

Status: Currently Official on 17-Feb-2025
Official Date: Official Prior to 2013
Document Type: USP Monographs
DocId: GUID-34575B6B-21EF-4A1F-9D18-E7AE242CADB5_1_en-US
DOI: https://doi.org/10.31003/USPNF_M30185_01_01
DOI Ref: 163uw

© 2025 USPC
Do not distribute

Erythromycin Delayed-Release Capsules

» Erythromycin Delayed-Release Capsules contain not less than 90.0 percent and not more than 115.0 percent of the labeled amount of erythromycin ($C_{37}H_{67}NO_{13}$).

Packaging and storage—Preserve in tight containers.

USP REFERENCE STANDARDS (11)—
[USP Erythromycin RS](#)

Identification—Prepare a test solution by mixing a quantity of finely ground Capsule contents with methanol to obtain a concentration of about 2.5 mg of erythromycin per mL. Prepare a Standard solution of [USP Erythromycin RS](#) in methanol containing 2.5 mg per mL. Apply separately 10 µL of each solution to a thin-layer chromatographic plate (see [Chromatography \(621\)](#)) coated with a 0.25-mm layer of chromatographic silica gel. Place the plate in an unlined chromatographic chamber, and develop the chromatogram in a solvent system consisting of a mixture of methanol and chloroform (85:15) until the solvent front has moved about 7 cm. Remove the plate from the chamber, mark the solvent front, and allow the solvent to evaporate. Spray the plate with a mixture of alcohol, *p*-methoxybenzaldehyde, and sulfuric acid (90:5:5). Heat the plate at 100° for 10 minutes, and examine the chromatogram, in which erythromycin appears as a black-to-purple spot: the R_f value of the principal spot obtained from the test solution corresponds to that obtained from the Standard solution.

DISSOLUTION (711)—Proceed as directed for *Procedure for Method B* under *Apparatus 1 and Apparatus 2, Delayed-Release Dosage Forms*.
Apparatus 1: 50 rpm.

Times: 60 minutes for *Acid Stage*; 60 minutes for *Buffer Stage*.

Procedure—Transfer the contents of 1 Capsule to the apparatus. Proceed as directed for *Acid Stage*, 900 mL of 0.06 N hydrochloric acid being placed in the vessel instead of 1000 mL of 0.1 N hydrochloric acid, and the apparatus operated for 60 minutes instead of 2 hours. Do not perform an analysis at the end of the *Acid stage*. Continue as directed for *Buffer Stage*, 900 mL of the pH 6.8 phosphate buffer being used instead of 1000 mL. Determine the amount of $C_{37}H_{67}NO_{13}$ dissolved after 120 minutes by assaying a filtered portion of the solution under test as directed under [Antibiotics—Microbial Assays \(81\)](#).

Tolerances—Not less than 80% (Q) of the labeled amount of $C_{37}H_{67}NO_{13}$ is dissolved in 120 minutes.

WATER DETERMINATION, Method I (921): not more than 7.5%, 20 mL of methanol containing 10% of imidazole being used in place of methanol in the titration vessel.

Assay—Proceed as directed under [Antibiotics—Microbial Assays \(81\)](#), using not less than 5 Capsules blended for about 3 minutes in a high-speed glass blender jar containing 200 mL of methanol. Add 300 mL of *Buffer B.3*, and blend again for about 3 minutes. Dilute an accurately measured volume of this stock solution quantitatively with *Buffer B.3* to obtain a *Test Dilution* having a concentration assumed to be equal to the median dose level of the Standard.

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ERYTHROMYCIN DELAYED-RELEASE CAPSULES	Julie Zhang Associate Science & Standards Liaison	BIO42020 Biologics Monographs 4 - Antibiotics
REFERENCE STANDARD SUPPORT	RS Technical Services RSTECH@usp.org	BIO42020 Biologics Monographs 4 - Antibiotics

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. PF 31(1)

Current DocID: GUID-34575B6B-21EF-4A1F-9D18-E7AE242CADB5_1_en-US
DOI: https://doi.org/10.31003/USPNF_M30185_01_01
DOI ref: [163uw](#)